It seems like everyone and their sister is taking a GLP-1 (“glucagon-like peptide-1 receptor agonists,” if you’re feeling nasty), or is at least thinking about it. These meds—which include Ozempic, ...

Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, ...

Haworth Lifestyle is part of Holland, Mich.-based Haworth Group, which booked $2.5 billion in sales for 2024, in line with ...

GLP-1 agonists may lead to increased nausea and vomiting in the early postoperative period after total hip arthroplasty, ...

To prevent muscle loss, more physicians are emphasizing the importance of fat loss vs weight loss for patients taking GLP-1 ...

Conducted in partnership with Morning Consult, the study found that GLP-1 users are increasingly prioritizing high-protein, ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Israeli startup ProFuse Technology, which specializes in the cultivation of muscle tissue in laboratory conditions, has launched a new technology and program for discovering drugs that prevent muscle ...

Flagship Pioneering-backed Sail Biomedicines has laid off 12 employees following a review of the company’s organizational ...